Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia

Abstract Background The combination of venetoclax (VEN) with hypomethylating agents (HMAs) has emerged as a new standard treatment for older or unfit patients with acute myeloid leukemia (AML). However, the predictive factors for VEN/HMA efficacy remain unclear. In our study, we performed the first...

Full description

Bibliographic Details
Published in:	European Journal of Medical Research
Main Authors:	Wenxiu Shu, Qianqian Yang, Donghua He, Yi Li, Jing Le, Qianqian Cai, Hui Dai, Liufei Luo, Bingrong Chen, Yuan Gong, Dian Jin
Format:	Article
Language:	English
Published:	BMC 2025-05-01
Subjects:	Acute myeloid leukemia KIT Venetoclax Hypomethylating agents Chemotherapy Prognosis
Online Access:	https://doi.org/10.1186/s40001-025-02637-w

Similar Items

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia
by: Yiming Cai, et al.
Published: (2025-07-01)

Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis
by: Yun Liu, et al.
Published: (2025-05-01)

Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience
by: Alicia Roldán Pérez, et al.
Published: (2022-07-01)

Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
by: Xuezhu Xu, et al.
Published: (2023-12-01)

Older Jehovah’s Witnesses with Acute Myeloid Leukemia: Hypomethylating Agents and Venetoclax as a Transfusion-Sparing Approach
by: Aditi Sharma, et al.
Published: (2025-06-01)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
by: Xubo Gong, et al.
Published: (2024-02-01)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
by: Xubo Gong, et al.
Published: (2023-06-01)

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience
by: Francesco Angotzi, et al.
Published: (2024-04-01)

The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
by: Matteo Piccini, et al.
Published: (2023-05-01)

Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study
by: Jie-Fei Bai, et al.
Published: (2025-06-01)

Combination of hypomethylating agents and inhibitor of BCL-2 in treatment of patients with relapsed acute myeloid leukemia: S.P. Botkin hospital experience
by: M. A. Granatkin, et al.
Published: (2023-03-01)

Case Report: Venetoclax combined with hypomethylating agents for the treatment of newly diagnosed with mixed-phenotype acute leukemia and a literature review
by: Ruihua Mi, et al.
Published: (2025-10-01)

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
by: Yunshuo Xiao, et al.
Published: (2024-12-01)

Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
by: Yifan Liu, et al.
Published: (2023-11-01)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
by: Matthew E. Tenold, et al.
Published: (2021-03-01)

Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia
by: E. V. Usikova, et al.
Published: (2023-01-01)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
by: Zheng Li, et al.
Published: (2022-02-01)

Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis
by: Yufeng Du, et al.
Published: (2023-08-01)

Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
by: Naval G. Daver, et al.
Published: (2023-03-01)

Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia
by: Xushu Zhong, et al.
Published: (2024-12-01)

Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
by: Kendall Diebold, et al.
Published: (2025-06-01)

A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients
by: Ludan Zhang, et al.
Published: (2024-05-01)

Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report
by: Kavya Sudireddy, et al.
Published: (2025-01-01)

Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells
by: Giulia Corradi, et al.
Published: (2024-05-01)

IDH2-mutated near ETP-ALL with aggressive leukemia cutis and brisk response to venetoclax and decitabine
by: Poorva Vaidya, et al.
Published: (2024-01-01)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
by: Zhangjie Chen, et al.
Published: (2023-03-01)

Comparative efficacy and safety in low-intensity treatment for acute myeloid leukemia in older patients: a systematic review and network meta-analysis
by: Wenze Li, et al.
Published: (2025-04-01)

The efficacy of varying doses of venetoclax combined with azacitidine for newly diagnosed adult acute myeloid leukemia in real-world settings: a single-center retrospective analysis
by: Yanjie Mao, et al.
Published: (2025-12-01)

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
by: Jingying Cui, et al.
Published: (2024-12-01)

Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis
by: Kimberly Guinan, et al.
Published: (2022-10-01)

Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial
by: Xiaohui Suo, et al.
Published: (2023-05-01)

Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia
by: Qingyang Liu, et al.
Published: (2025-02-01)

Research progress of anti-apoptotic inhibitor venetoclax in treatment of myeloid leukemia
by: XIANG Caixia, HUANG Bintao, HAO Jian
Published: (2023-05-01)

Efficacy and safety of hypomethylating agents in the treatment of AML/MDS patients relapsed post allogenetic hematopoietic stem cell transplantation
by: Yaxin Wang, et al.
Published: (2024-12-01)

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
by: Mariarita Sciumè, et al.
Published: (2023-03-01)

Real-world experience of venetoclax target dosing with concomitant posaconazole in adult patients with acute myeloid leukemia
by: Tracelyn Freeman, et al.
Published: (2025-09-01)

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
by: Xiang Zhang, et al.
Published: (2021-05-01)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
by: Xi Xu, et al.
Published: (2023-10-01)

Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
by: Dian Jin, et al.
Published: (2024-07-01)

Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management
by: Tatsunori Goto, et al.
Published: (2025-03-01)